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Abstract 
Autosomal Dominant Hypercholesterolemia (ADH) is characterized by isolated elevation of 
plasmatic LDL cholesterol associated with high risk of premature cardiovascular disease. 
Mutations in LDLR, APOB and PCSK9 genes have been shown to cause ADH. We now 
report further genetic heterogeneity of ADH through the study of a large French family in 
which the involvement of theses three genes was excluded. A genomewide scan mapped the 
disease-causing gene, named HCHOLA4, at 16q22.1 in a 7.89 Mb interval containning 154 
genes with a maximum lod-score of 3.9. To reduce the linked region, we genotyped 18 
smaller nonLDLR/nonAPOB/nonPCSK9-ADH families at the HCHOLA4 locus. Six families 
did not exclude linkage to the locus, but none allowed reduction of the disease interval. The 
154 regional genes were sorted according to the function of the encoded protein, and tissue 
expression profiles, and 57 genes were analysed through sequencing of their coding region 
and close flanking intronic parts. No disease-causing mutation was identified in these 
families, particularly in the LCAT gene. Finally, our results also show the existence of other 
ADH genes since 9 families were neither linked to the LDLR, APOB, PCSK9 genes nor the 
new HCHOLA4 locus. 
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Autosomal co-Dominant Hypercholesterolemia (ADH, OMIM #143890) is one of the most 
frequent inherited disorders in man with a frequency of 1/500 for heterozygotes in Western 
populations. It is characterized by a selective increase of Low Density Lipoprotein (LDL) 
particles in plasma giving rise to tendon and skin xanthomas, arcus cornea, and premature 
mobidity and mortality from cardiovascular complications. This disease has proven to be 
genetically heterogeneous and associated with defects in 2 different genes: LDLR (low density 
lipoprotein receptor) (1,2), and APOB (apolipoprotein B-100) (3). Our team pioneered the 
hypothesis that the disease was genetically more heterogeneous. We mapped a third major 
locus at 1p34.1-p32(4) and went on to show that it encodes PCSK9 (Proprotein Convertase 
Subtilisin/Kexin type 9) (5). Altogether, we identified 7 mutations in 8 families (5,6, JPR 
personal data) and showed that mutations in the PCSK9 gene account for only 1.8 % of gene 
defects in a sample of 392 ADH families studied in our laboratory. Subsequently, Cohen et al. 
showed that mutations within the gene are also involved with a dominant form of 
hypocholesterolemia (7). Targets of PCSK9 convertase are still unknown and its biological 
function is still not clear, although it is now known to enhance the degradation of the low 
density lipoprotein receptor (8). 
While investigating ADH families, we identified a group of families neither harboring 
mutations within the three major genes nor linked to any of these genes.We now report one of 
these families, a large French pedigree, in which we postulated the involvement of a fourth 
gene we named HCHOLA4. The objective of this study was to localize and possibly identify 
ADH disease loci additional to the three major loci known. 
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Materials and Methods 
Familly recruitment and disease ascertainment 
Hypercholesterolemic families were recruited by the French National Research Network on 
Hypercholesterolemia. For probands, the following selection criteria were used: total 
cholesterol and apoB values above the 95 th percentile when compared to a sex- and age-
matched French population (personal data from Institut Régional pour la Santé, Tours-La 
Riche, France), triglycerides below 1.5 mmol/L, personal and/or documented familial 
xanthomas, xanthelasmas, and/or arcus corneae, and early coronary artery disease. Lipid 
measurements were repeated to ascertain the existence of primary type IIa 
hypercholesterolemia. Families were investigated at large to confirm the presence of ADH. 
Blood samples were obtained from the index patient and his, her relatives for isolation of 
DNA. The study was performed in accordance with French bioethic regulations and written 
informed consent  was given by all subjects, and when appropriate, by parents or guardians. 
 
Genomewide scan and linkage analysis 
A genomewide scan was performed using 232 polymorphic microsatellite markers spaced at 
20 cM intervals on autosomes (9). All marker-typing data were collected blindly and 
independently by four of us. A second genomewide scan was performed using a GeneChip® 
10K Array (Affymetrix chips, GeneChip® Human Mapping 10K Array Xba 142) in 
collaboration with “Centre National de Génotypage” (Evry, France). We used parametric 
linkage in two situations: the first, an “affected-only” analysis where all related family 
members were given either an affected or an unknown disease status; the second, a “whole 
family” analysis where all related familly members were given an affected, unaffected or 
unknown status as provided by referring clinicians and in agreement with clinical and 
biological data. Parametric linkage analyses were performed with the following parameters: 
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(1) autosomal dominant transmission of the disease trait, (2) reduced penetrance of 0.9 for 
heterozygotes (or complete penetrance for the affected-only analyses) and (3) frequency of 
the disease allele of 0.004% (close to the frequency of PCSK9 mutants). The power of the 
families for linkage was evaluated using the FastSlink v2.51 program (10). We used Pedcheck 
(11) to detect Mendelian inheritance errors. SuperLink v1.5 and SimWalk v2.91 programs 
were used to compute two-point and multipoint LOD scores (12,13). All these programs were 
run with the easyLinkage Plus v5.00 package (14). Additional model-free analyses were 
realized with the GENEHUNTER program that performs a complete multipoint to infer the 
degree of identity-by-descent sharing among all affected family members at each map point 
(15). We used GENEHUNTER-PLUS,  a modified version of this program , that has been 
shown to be less conservative, particularly when data are less than perfectly informative (16). 
This program calculates a semi-parametric LOD score (ghp-LS) by using a single parameter 
that is the measure of the inheritance vector in the pedigree and allele sharing. 
 
Candidate genes investigation 
DNA was extracted from venous blood using a technique described by Collod et al.(17). A 
selection of 57 regional candidate genes was sequenced (coding regions and close flanking 
intronic parts) as previously reported (5). Primer sequences are available on request. 
 
LCAT activity measurement 
Lecithin Cholesterol Acyltransferase (LCAT) activity in the plasma was measured by a non-
radioactive endogenous cholesterol esterification method (18). Briefly, it consists in 
measuring the decrease in plasma free cholesterol content following incubation at 37°C. 
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Results 
Identification of a nonLDLR/nonAPOB/nonPCSK9 ADH Family 
Among 69 consecutive nonLDLR/nonAPOB/nonPCSK9 families identified in our laboratory, 
one family was large enough to enable genomewide mapping.The recruitment of the HC6 
family  was initiated through the female proband II-4 who presented a total cholesterol value 
of 3.64 g/L (9.39 mmol/L) at 54 years of age without medication. We enlarged the family to 
30 individuals over 4 generations,  thus exploring 23 meioses (Table 1 and, Figure 1). Several 
cardiovascular accidents were reported in the previous generations. Clinical examination of 
affected members revealed no xanthoma, xanthelasma or corneal arcus. Carotid intimal-
medial thickness was elevated for patient II-1 whereas it was normal for his sister II-4 (data 
not shown). Ten family members presented elevated blood cholesterol with isolated 
hyperLDLemia; 13 family members and 5 spouses showed no clinical or biological anomaly 
and were considered non affected. Finally, a father  II-9 and son (III-14) were scored as 
“unknown” for linkage analysis because of high triglycerides (2.53 mmol/L) in the father. 
Distributions of total and LDL cholesterol values in all tested family members were bimodal, 
thus compatible with an autosomal dominant transmission of the disease (data not shown). 
The candidate gene approach excluded genetic linkage between the ADH phenotype and any 
of the three ADH-causing genes identified so far. Indeed, regional haplotypes constructed in 
the HC6 family for polymorphic markers covering LDLR (19p13.2), APOB (2p24.1), and 
PCSK9 (1p32.3) genes showed no cosegregation of a particular allelic association with the 
ADH phenotype. Furthermore, with a “whole family” linkage analysis, exclusion lod score 
values of - 4.95, -3.47 and - 2.49 were obtained for the LDLR, APOB and PCSK9 genes, 
respectively. Finally, no deleterious mutation was observed after sequencing the LDLR, 
APOB, and PCSK9 genes, and no major rearrangement was found in the LDLR gene (data not 
shown). 
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Linkage analysis 
One hundred thousand simulations were performed to evaluate the power and the relevance of 
a genomewide linkage scan in the HC6 family. In the “affected-only” analysis, the average 
expected LOD score was 1.60 and the maximum expected LOD score was 2.41. In the “whole 
familly” analysis, the average expected LOD score was 3.18 and the maximum expected LOD 
score was 4.81, indicating that the statistically significant threshold of 3 could be reached with 
this single family with 51.3% of maximum lod scores greater than 3.3 (empirical p=0.010), 
and for thresholds of 3.7 or 3.9, empirical p= 0.001. Among the 232 microsatellite markers 
initially tested in the “whole familly” analysis, seven had LOD scores above 1.2: markers 
D8S263 (LOD=1.41, θ=0), D10S186 (LOD=1.29, θ=0), D12S310 (LOD=1.43, θ=0.15), 
D12S87 (LOD=1.32, θ=0.2), D16S3107 (LOD=3.77, θ=0), D16S515 (LOD=1.36, θ=0) and 
D20S200 (LOD=1.38, θ=0.15). 
To confirm and further investigate possible linkage in these regions, 500 SNPs as well as 12 
additional microsatellite markers were used. Convincing exclusion data were obtained for 
chromosomes 8, 10, 12 and 20. At 16q22, seven additional microsatellite markers and 100 
SNPs of the 16q22 region were tested to saturate and to delimit a disease interval. Results of 
this analysis showed high LOD scores for nine of the new markers (Table 2 and Supplemental 
Table 1). In the “affected-only” analysis, five markers, D16S3031, rs725131, D16S3107, 
D16S3067 and D16S3018, had LODθ =0 scores of  2.11, 1.85, 2.41, 2.41 and 1.98, respectively 
(Supplemental Table 1). In the “whole family” analysis, LODθ =0 scores for rs725131, 
D16S3107, D16S3067 and D16S3083 raised to 3.36, 3.77, 3.91 and 2.41, respectively, 
whereas the maximum LOD score for D16S3031 was reduced to 1.46 at θ =0.10 (Table 2).  
To investigate whether 16q22.1 linkage could result from the use of an inaccurate model, we 
performed model-free analyses with GENHUNTER-PLUS ( from marker D16S3043 to 
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D16S518) in affected individuals of the HC6 family. A semi-parametric LOD score (ghp-LS) 
was calculated. The ghp-LS was null at markers D16S3043 and D16S518 thus excluding 
linkage to these two markers. The ghp-LS was positive and maximal (1.63) from markers 
D16S3031 to D16S515 (data not shown). 
Regional haplotype construction allowed the identification of  a common region for all 
affected members from D16S3043 to D16S518 (Figure 1). Indeed, recombinational events 
were oberved in patient II-5 for the proximal border (between D16S3043 and D16S3031) and 
in patient II-1 for the distal border (between rs254770 and D16S518). Non-affected 
recombinants allowed reduction to a minimum interval of 8.39 Mb between markers 
D16S3031 and D16S3018 (Figure 1). Indeed, recombinational events were found in members 
II-11 and III-4 for the proximal border (between D16S3031 and rs725131) and in member III-
10 for the distal border (between D16S3067 and D16S3018). Subject III-11 (non-affected) 
also inherited the disease-associated haplotype and thus highly probably displays incomplete 
penetrance of the HCHOLA4 disease. Phenotypically unclassified patients (II-9 and III-14) 
did not carry the disease haplotype. The regional multipoint LOD score analysis gave a 
maximum value of 3.81 and allowed the identification of a minimum interval of 7.89 Mb 
between 64 687 100 and 72 127 100 bp at 16q22 (Figure 2). 
To reduce the linked region, we genotyped polymorphic markers of the HCHOLA4 locus in 
18 ADH families that showed exlusion of the LDLR, APOB and PCSK9 genes as well as the 
absence of mutation within these genes (Table 3). These 18 families represented a total of 75 
meioses with 74 affected and 49 non-affected subjects. Three families (HC32, HC122 and 
HC218) were non informative. Nine families (HC14, HC35, HC42, HC73, HC126, HC138, 
HC257, HC374 and HC438) showed exclusion of the locus. The six remaining families 
(HC38, HC49, HC120, HC136, HC205 and HC266) did not exclude linkage to the 
HCHOLA4 locus but were not large enough to provide significant linkage. Furthermore, none 
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of them showed recombinational events in the disease interval. In effect, the recombinational 
event found in family HC136 occured between markers D16S3031 and D16S3019 (position 
64 686 681 bp) (data not shown), and thus was distal to the regional boundary obtained with 
subject III-4 from the HC6 family, that occured between markers D16S3031 and rs725131 
(position 65 143 211 bp) (Table 2, Figure 1). 
 
Analysis of regional candidate genes 
An inventory of all the genes and ORFs present between these two positions was drawn up 
using data from the UCSC Genome Browser (http://www.genome.ucsc.edu/cgi-
bin/hgGateway), the Genatlas database (http://www.dsi.univ-paris5.fr/genatlas/) and the 
Ensembl Database (http://www.ebi.ac.uk/ensembl/). This study showed that the disease 
interval contains 154 genes (Supplemental Table 2). The first gene investigated was the LCAT 
gene since it encodes a major actor of cholesterol metabolism. No mutation was identified in 
affected members of the HC6 family after sequencing of the 6 exons and intronic flanking 
regions of the gene. Furthermore, LCAT enzymatic activity was tested in two affected 
members of the HC6 family (subjects II-4 and III-5) and was not significatively different from 
that of controls (82.30 ±5.59 versus 70.00 ±3.54 nmol CE/h/mL of plasma for controls, p = 
0.07). 
Several genes within the locus were good candidates and we defined a priority for analysis 
according to the function of the encoded proteins and their tissue expression. We tested the 
coding sequence of 57 candidate genes by direct sequencing (Supplemental Table 2). No 
deleterious variation was identified. However, this systematic sequencing allowed the 
identification of new polymorphisms that were used to comfort regional haplotypes, and to 
reduce the common interval. We identified one polymorphism in C16orf48 ( c.780A>G). Its 
frequency was estimated at 0.49 by direct sequencing of 60 healthy individuals. All carriers of 
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the affected haplotype in the HC6 family shared this polymorphism. A two-point linkage 
analysis gave a LOD score of 3.52 (θ=0). Interestingly, this gene is located close to marker 
D16S3067 for which we obtained the highest regional LOD score. 
 
 
Discussion 
In the present study, a genomewide scan performed in a single large French family mapped  a 
fourth ADH gene (different from LDLR, APOB and PCSK9) at 16q22.1. The highest LOD 
scores of 3.77 (θ=0) and 3.36 (θ=0) were obtained for markers D16S3107 and rs725131, 
respectively, with the “whole familly” analysis to maximize the number of investigated 
meioses. Mapping was confirmed by a multipoint analysis that gave significative LOD scores 
as well. Furthermore, no other region of the genome showed LOD score values as important 
as these. Haplotype construction in the HC6 family allowed delineation of a critical region 
between markers D16S3043 and D16S518 considering only affected members, and between 
markers D16S3031 and D16S30106 when unaffected individuals were also taken into 
account. Subject III-11, who carries the disease-associated haplotype but presents a normal 
phenotype, may illustrate the well documented incomplete penetrance of ADH. Indeed, there 
is an extreme variability of the hypercholesterolemic phenotype with well documented cases 
of incomplete penetrance probably due to the effect of modifier factors. For example, Sass et 
al. reported a French Canadian family with a 5 kb deletion in the LDLR gene with several 
carriers of the mutation presenting normal cholesterol values (19). In the same way Hobbs et 
al. described a large Puerto Rican family carrying the p.Ser156Leu (now p.Ser177Leu 
according to the international nomenclature) mutation of the LDLR gene (20). In this family, 
penetrance of the disease could be estimated at 0.68 (13/19), since six subjects were non-
manifesting carriers of the mutation. As well, in our first report of the p.Ser127Arg mutation 
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in the PCSK9 gene, one carrier of the mutation displayed normal cholesterol levels contrary to 
the other family members carriers of the disease-causing mutation who were 
hypercholesterolemic (5). 
To reduce the linked region, 18 smaller ADH families that showed exlusion of the 
involvement of the LDLR, APOB and PCSK9 genes were studied. Only 6 did not exclude 
linkage to the HCHOLA4 locus but were not large enough to independantly provide 
significant linkage. Furthermore, no recombinational event was detected that would have 
allowed the reduction of the disease interval. Recruitment of new family members and new 
families is now necessary to replicate significant linkage and to define a smaller inteval. 
None of the recent genomewide association or linkage studies (21-25) identified any loci 
fulfilling our two search criteria: 1) affecting LDL (only lipoprotein elevated in the 
HCHOLA4 families), and 2) localized within positions 64 687 100 – 72 127 000 bp at 16q22. 
Three genomewide association studies established an association between loci localized 
within the HCHOLA4 locus at 16q22.1 reported here, and variation in HDL concentrations 
(21-23). These loci are generally considered to reflect association of HDL levels with the 
LCAT gene. Mutations in the LCAT gene are associated with Fish Eye disease (OMIM 
#136120). Fish Eye disease is characterized by normal serum cholesterol and raised serum 
triglycerides, VLDL, and LDL triglycerides whereas HDL cholesterol is reduced. Even 
though Fish Eye disease and ADH present different phenotypes, we explored the LCAT gene 
as a HCHOLA4 candidate because of its involvement in cholesterol metabolism. 
Unsurprisingly, no mutation was found in the affected subjects of the HC6 family. 
Furthermore, LCAT enzymatic activity of two affected family members was not significantly 
different from that of controls. Thus, involvement of the LCAT gene was clearly excluded.  
Our results reveal the existence of a new partner of either LDL receptor-mediated endocytosis 
or intracellular trafficking, or even a new and different endocytic pathway. .Better knowledge 
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has been gained in recent years on the molecular basis of transmembrane traffic of cargo 
proteins. The clathrin-dependent pathway, involved in the endocytosis of receptor-bound LDL 
particles, is now known to involve adaptors (heterotetrameric protein complexes or AP2 
complexes) that are responsible for cargo sorting (27). However other traffic pathways have 
been defined either associated with coated vesicles (COPI and COPII) or caveolae (28). Also 
noteworthy is the protein encoded by the recently cloned ARH gene (MIM #605747). Its 
protein product called LDLR adaptor protein 1contains a phosphotyrosine binding domain 
that is also found in adaptator proteins and that could bind the cytoplasmic NPXY motif of the 
LDL receptor. Mutations of the ARH gene are found in patients presenting with the autosomal 
recessive form of familial hypercholesterolemia (29). In this context, several genes at 16q22.1 
were also excellent functional candidates. Among these, 5 genes were studied first: 
- The AP1G1 gene encodes the adaptor-related protein complex 1, gamma-1 that belongs to 
the adaptor complexes large subunit family, involved in vesicles transport from the trans-
Golgi network to lysosomes (30). 
- The VPS4A gene encodes a AAAtype ATPase belonging to the family of vacuolar sorting 
proteins originally identified in yeast. Genetic studies led to the identification of a subset of 
yeast “vps” mutants that accumulate an exagerated late endosome known as the “class E” 
compartment. These mutants were found to be defective in multivesicular body formation 
(31). 
- The RRAD gene encodes a ras-related GTPase already involved in diabetes and that might 
be involved in LDL receptor endocytosis since GTPase Rho plays a role in cellular uptake of 
LDL by human skin fibroblasts (32). 
- The ATP6V0D1 gene (vesicular ATPase), encodes a vacuolar proton-ATPase and is possibly 
involved in the transport from late endosome to lysosomes of membrane proteins (33). 
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- The FLJ12076 gene encodes a homolog of LIN-10 involved in EGF receptor (LET-23) 
membrane localization in C. elegans (34). LIN-10 protein contains a PDZ domain known to 
interact with cytoplasmic tails of membrane proteins (35). 
No mutation was found in any of these genes nor among the 52 other regional genes that we 
studied. However, this does not totally exclude the possibility that one may very well be the 
causative gene since only exons and their flanking intronic regions were sequenced. 
The present study gives evidence of the existence of a new gene involved in the pathogenesis 
of ADH. The existence of a greater level of genetic heterogeneity is in agreement with recent 
reports since the proportion of ADH subjects without an identified mutation ranges from 12% 
to 72% depending on the study (36). Such a large difference in mutation identification is 
probably due to different sample sizes, to heterogeneous clinical definitions and screening 
protocols. Overall, the best estimated proportion of individuals without a mutation in any of 
the three identified ADH genes is 15.25% (36). This group of new forms of ADH is very 
probably itself heterogeneous and the proportion of HCHOLA4-affected individuals may not 
be more important than that of PCSK9 carriers that we estimated at 1.5 % (36). HCHOLA4-
linked ADH may thus be considered as a very rare form of ADH. Whatever its function, the 
HCHOLA4 protein may be a player in the pathway that involves the convertase PCSK9 and 
thus be also involved in the intracellular traffiking of the LDL receptor. If so, its identification 
would help to elucidate the pathophysiology of both PCSK9-linked and HCHOLA4-linked 
ADH. Furthermore, as a novel protein implicated in the regulation of cholesterol metabolism, 
HCHOLA4 might constitute a new target for hypocholesterolemic treatment. 
In conclusion, we report the detection and chromosomal localization of the fourth gene 
involved in ADH at 16q22.1. Recruitment of new families is now required to define a smaller 
linked region and to focus research on a reduced number of genes. Finally, our results also 
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show the existence of other ADH genes through the identification of 9 families unlinked to 
either the LDLR, APOB, PCSK9 or the new HCHOLA4 gene. 
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Legends 
 
 
Figure 1: Regional haplotype of the HCHOLA4 locus in the HC6 family. 
Blackened symbols represent affected subjects, white symbols represent unaffected subjects 
while individuals with undetermined status are in grey. 
 
Figure 2: Multipoint LOD scores of the HCHOLA4 locus. 
The parameters used for this analysis were: dominant inheritance, incomplete penetrance (0.9) 
and frequency of the disease-causing allele at 0.004% (SimWalk v2.91).  
Subject Gender Age Total Cholesterol LDL-Cholesterol Triglycerids
Status in linkage 
analyses
I-2 F 81 10.09 7.69 1.40 Affected
II-1 M 59 8.28 6.40 1.70 Affected
II-2 F 56 5.86 3.87 1.22 Non-affected
II-3 M 61 5.99 4.10 1.70 Non-affected
II-4 F 54 9.39 7.25 1.09 Affected
II-5 M 56 9.60 7.10 1.08 Affected
II-6 F 54 6.32 3.48 0.63 Non-affected
II-7 M 49 4.90 3.41 1.00 Non-affected
II-8 F 45 6.81 4.95 1.69 Affected
II-9 M 47 9.83 6.71 2.53 Unknown
II-10 F 44 5.39 3.59 0.50 Non-affected
II-11 M 40 5.88 4.10 0.50 Non-affected
III-1 M 28 6.32 4.75 1.31 Affected
III-2 M 26 7.17 5.55 1.01 Affected
III-4 F 36 3.41 2.09 0.91 Non-affected
III-5 M 31 7.48 5.08 2.39 * Affected
III-6 F 34 5.78 3.79 0.50 Non-affected
III-8 F 32 7.69 5.78 1.46 Affected
III-9 M 23 4.52 2.99 1.04 Non-affected
III-10 M 30 5.60 3.46 0.89 Non-affected
III-11 M 23 4.70 3.30 0.70 Non-affected
III-12 M 23 4.28 2.99 0.90 Non-affected
III-13 M 14 3.69 2.40 0.50 Non-affected
III-14 M 16 5.88 4.41 0.99 Unknown
III-15 F 23 5.29 2.99 0.80 Non-affected
IV-1 M 14 2.99 1.60 1.00 Non-affected
IV-2 F 11 3.30 1.81 0.70 Non-affected
IV-3 F 7 2.30 0.90 1.00 Non-affected
IV-4 F 11 4.90 3.10 0.80 Non-affected
IV-5 M 2 7.35 6.24 0.98 Affected
* Non fasting.
Table 1 : Lipids values for subjects of the HC6 family. The proband is indicated in bold. Values are given in mmol/L.
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MARKER Position (bp) 0.00 0.05 0.10 0.15 0.20 0.25 0.30
D16S3043 64 049 873 - 64 049 998  -4.82  -1.16  -0.68  -0.41  -0.25  -0.14  -0.08
D16S3031 64 338 902 - 64 339 161  -1.29 1.32 1.46 1.44 1.34 1.18 0.98
rs725131 65,143,211 3.36 3.17 2.92 2.62 2.28 1.91 1.51
D16S3107 66 215 439 - 66 215 732 3.77 3.46 3.14 2.81 2.45 2.07 1.67
D16S496 67 506 219  -67 506 438 1.23 1.15 1.02 0.84 0.64 0.42 0.21
D16S3067 67 666 169 - 67 666 312 3.91 3.59 3.26 2.91 2.54 2.14 1.73
rs904809 68,508,792 0.77 0.80 0.79 0.75 0.68 0.60 0.50
rs722579 69,085,725 0.92 0.96 0.94 0.89 0.82 0.73 0.62
rs1004330 69,590,464 1.17 1.06 0.94 0.82 0.69 0.56 0.42
rs951939 70,367,035 1.16 1.18 1.15 1.08 0.99 0.88 0.74
rs952160 70,523,226 1.83 1.80 1.71 1.59 1.44 1.27 1.07
D16S3106 70 745 261 - 70 745 460 1.62 1.51 1.34 1.13 0.88 0.62 0.36
rs811047 70,818,194 1.25 1.17 1.03 0.86 0.66 0.45 0.25
rs1383361 72,231,717 1.41 1.28 1.14 1.00 0.85 0.70 0.53
D16S512 72 625 213 - 72 625 415 0.62 0.65 0.64 0.59 0.52 0.43 0.33
D16S3018 72 730 203 - 72 730 462 1.72 1.85 1.85 1.76 1.62 1.42 1.17
rs725710 73,431,014 1.27 1.15 1.02 0.89 0.75 0.61 0.46
D16S538 74 438 373 - 74 438 918 1.76 1.58 1.39 1.20 0.99 0.79 0.59
D16S3083 75 042 911 - 75 043 109 2.41 2.20 1.99 1.76 1.52 1.27 1.01
D16S515 75 074 576 - 75 074 715 1.36 1.47 1.48 1.42 1.33 1.19 1.02
D16S3097 75 946 568 - 75 946 765 1.48 1.32 1.17 1.01 0.86 0.72 0.57
D16S3138 76 161 268 - 76 161 492 1.79 1.76 1.67 1.55 1.41 1.24 1.04
rs254770 76,435,072  -4.48  -0.67  -0.44  -0.31  -0.22  -0.16  -0.11
D16S518 76 695 528 - 76 695 807  -11.64  -1.53  -0.64  -0.18 0.08 0.22 0.27
LOD score at q =
Table 2 : Two-Point Parametric Linkage Analysis in the whole HC6 family. 
The parameters used for this analysis were: dominant inheritance, reduced penetrance of the disease trait (0.9) and 
frequency of the disease-causing allele at 0.004%  (SuperLink v1.5).
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6
Nb. D16S3031 D16S3107 D16S3067 D16S3106 D16S3018
Familly Subjects Affected meiosis av. max. 64,338,902 66,215,433 67,666,169 70,745,261 72,730,203
HC14 13 10 9 1.29 1.80  -7.84  -7.19  -6.85  -9.16  -6.49
HC32 4 3 2 0.12 0.26  -0.74  -0.74  -0.74  -0.74 na
HC35 5 4 3 0.45 0.60  -1.85  -2.39  -2.26  -2.71 na
HC38 4 3 2 0.23 0.30 0.30 0.30 0.30 0.30 0.30
HC42 6 4 5 0.55 0.81  -2.85  -2.29  -2.15  -2.89  -2.99
HC49 4 3 2 0.23 0.30 0.30 0.30 0.30 0.30 0.30
HC73 15 4 10 1.06 1.69  -8.18  -7.16  -6.48  -10.06  -7.29
HC120 4 3 2 0.22 0.30 0.30 0.30 0.30 0.28 0.26
HC122 8 4 5 0.70 1.12  -0.19  -0.14  -0.12  -0.10  -0.04
HC126 11 3 6 0.59 1.21  -2.21  -3.21  -3.21  -1.65  -0.62
HC136 5 4 3 0.44 0.60  -2.51 0.60 0.60 0.60 0.60
HC138 6 5 4 0.53 0.9  -6.57  -5.14  -4.95  -5.36  -4.87
HC205 6 3 4 0.50 0.86 0.86 0.86 0.86 0.86 0.86
HC218 4 3 2 0.11 0.26  -0.74  -0.74  -0.73  -0.74  -0.74
HC257 5 4 3 0.44 0.60  -1.75  -2.14  -2.13  -2.67  -1.24
HC266 5 3 3 0.33 0.56 0.56 0.56 0.56 0.56 0.56
HC374 8 5 4 0.68 0.9  -1.85  -1.80  -1.84  -2.41  -2.55
HC438 10 6 6 1.18 2.52  -4.88  -3.57  -3.26  -3.18  -8.59
Nb. ELOD
SimWalk multipoint LOD (q = 0)
Table 3 : SimWalk multipoint parametric linkage analysis of the HCHOLA4 locus in 18 families.
